Amsterdam (ots/PRNewswire)

Norgine B.V. today announced that its UK affiliate has received funding for ENDOCUFF VISION® through the NHS Innovation Technology Payment 2018/19 (ITP) scheme. The NHS ITP Programme aims to support the NHS in adopting innovation by removing financial or procurement barriers to uptake of innovative products or technologies and is a competitive process.

(Logo: http://mma.prnewswire.com/media/597589/Norgine_Logo.jpg )

(Photo: https://mma.prnewswire.com/media/634543/Norgine_ENDOCUFF_VISION.jpg )

ENDOCUFF VISION® is a single use device attached at the end of the colonoscope that gives an optimal view of the entire colon by retracting folds during withdrawal. ENDOCUFF VISION® will be funded in colonoscopies conducted as part of the bowel cancer screening programme.

ENDOCUFF VISION®

ENDOCUFF VISION® significantly improved adenoma detection rate and colorectal cancer detection during colonoscopy in bowel cancer screening patients.[i]

Colorectal cancer is the 4th most common cancer in the UK, accounting for 12% of all new cancer cases. 1 in 14 men and 1 in 19 women will be diagnosed with bowel cancer during their lifetime.[ii]

In the UK and Europe, ENDOCUFF VISION® is available through Norgine and in other parts of the world the product is available through business partners. Norgine owns a majority stake of Arc Medical Design Ltd, the originator of ENDOCUFF VISION®.

References:

i. Ngu WS, et al. Gut 2018;66:1-9. doi:10.1136/gutjnl-2017-314889

ii. Cancer Research UK. http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/bowel-cancer . Accessed 5 April 2018.

Media Contact:

Isabelle Jouin, T: +44(0)1895-826237

Follow us @norgine